Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Decreases By 89.4%

NeuroMetrix, Inc. (NASDAQ:NURO) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 1,200 shares, a decline of 89.4% from the March 31st total of 11,300 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 48,700 shares, the days-to-cover ratio is currently 0.0 days.

NeuroMetrix Stock Performance

NURO stock traded up $0.08 during trading on Thursday, hitting $4.41. The stock had a trading volume of 7,134 shares, compared to its average volume of 43,024. The company’s 50 day moving average price is $3.87 and its two-hundred day moving average price is $3.79. NeuroMetrix has a 1-year low of $2.70 and a 1-year high of $11.55. The stock has a market cap of $8.78 million, a price-to-earnings ratio of -0.71 and a beta of 2.26.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. NeuroMetrix had a negative net margin of 110.64% and a negative return on equity of 31.31%. The company had revenue of $1.32 million for the quarter.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a research note on Thursday, April 18th. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroMetrix stock. Cerity Partners LLC bought a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned 2.80% of NeuroMetrix as of its most recent filing with the SEC. 19.40% of the stock is currently owned by institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.